Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
05 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
13 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
28 oct. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
23 oct. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
19 août 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
08 août 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update